Value-based cancer care platform Thyme Care announced it secured $60 million in Series B funding co-led by Foresite Capital and Town Hall Ventures, bringing its total raise to over $80 million.
Current investors Andreessen Horowitz BIO + Health, Casdin Capital, Frist Cressey Ventures and AlleyCorp participated in the round.
Town Hall Ventures' cofounder and general partner David Whelan will join Thyme Care's board of directors, as will Elizabeth Canis, executive advisor at Foresite Capital.